@article{oai:nagasaki-u.repo.nii.ac.jp:00021863,
 author = {Oka, Mikio},
 issue = {2-4},
 journal = {Acta medica Nagasakiensia},
 month = {Dec},
 note = {For active cancer immunotherapy by alveolar macrophage (AM) targeting, the usefulness of polysaccharide-coated liposomes was examined in an animal model, and the morphological changes in activated AM were observed using scanning electron microscopy. Among the liposomes tested, cholesterol-mannancoated large unilamellar liposomes (CHM-LUV) had the highest targetability to the lung. MDP-L18 or MA-CDA as synthetic immunoactivators, were encapsulated within CHM-LUV. After the intravenous injection of encapsulated or nonencapsulated, MA-CDA or MDP-L18, the antitumor activity of C57BL/6 AM against Lewis lung carcinoma (3LL) was measured in vitro. The encapsulated immunoactivators enhanced the antitumor activity of AM more effectively and for a longer time than the nonencapsulated ones. Concurrent with activation by MA-CDA, AM showed signs of very high surface activity, such as prominent ruffles, elongated filopodia and thickened lamellipodia. Some of the AM showed strong attachment to 3LL cells in vitro. No prolonged survival was obtained with the treatment of 3LL-bearing mice by CHM-LUV (MA-CDA) alone. However, these date demonstrated that polysaccharide- coated liposomes containing immunoactivator might be useful in future active cancer immunotherapy by AM targeting., Acta medica Nagasakiensia. 1989, 34(2-4), p.88-98},
 pages = {88--98},
 title = {Enhancement of Antitumor Activity in Mouse Alveolar Macrophages by Immunoactivators Encapsulated within Polysaccharide-coated Liposomes},
 volume = {34},
 year = {1989}
}